2,237
Views
0
CrossRef citations to date
0
Altmetric
Laboratory Study

Human umbilical cord mesenchymal stem cell exosomes alleviate acute kidney injury by inhibiting pyroptosis in rats and NRK-52E cells

, , , , , , & show all
Article: 2221138 | Received 07 Mar 2023, Accepted 30 May 2023, Published online: 09 Jun 2023
 

Abstract

Human umbilical cord mesenchymal stem cells (hucMSCs) have been shown to improve kidney injury. Exosomes have been indicated to be important mediators of renal protection in MSC therapy. In spite of this, the mechanism remains unclear. Our study investigated how exosomes derived from hucMSCs (hucMSC-Ex) improve acute kidney injury (AKI). Exosomes were extracted by using an ultracentrifugation technique and identified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot. Twenty-four male SD rats were randomly divided into four groups: sham group, sham + hucMSC-Ex group, ischemia–reperfusion injury (IRI) group, and IRI + hucMSC-Ex group. In vitro, we treated rat proximal renal tubular epithelial cell line (NRK-52E) with cisplatin to mimic in vivo models of AKI. The NRK-52E cells were treated with or without 160 μg/mL hucMSC-Ex, and 1 µg/mL cisplatin was added after 9 h. Cells were harvested after 24 h. In the IRI group, the levels of serum creatinine (Scr) and blood urea nitrogen (BUN) were increased; renal tubules were dilated, epithelial cells were vacuolated, and collagen fibers were deposited in the renal interstitium. After treatment with cisplatin, the NRK-52E cells displayed pyroptotic morphology characterized by pyroptotic bodies. The protein expression levels of fibronectin, α-smooth muscle actin (α-SMA), vimentin, gasdermin D (GSDMD), caspase-1, interleukin-1 (IL-1β) and NLRP3 in IRI tissues and in cisplatin treatment NRK-52E cells were significantly upregulated. However, after the hucMSC-Ex intervention, kidney injury was effectively improved in vivo and in vitro. The current study shows that pyroptosis is involved in AKI and that hucMSC-Ex improves AKI by inhibiting pyroptosis.

Author contributions

All authors have read and agreed to the published version of the manuscript. Conceptualization and data curation: Lianju Shen and Yonghong Wan; formal analysis: Yonghong Wan and Jin Luo; funding acquisition: Yi Hua and Guanghui Wei; methodology: Lianju Shen and Yihang Yu; project administration: Yi Hua and Yihang Yu; resources: Yonghong Wan; software: Chengjun and Sheng Wen; supervision: Yi Hua; writing – original draft: Yonghong Wan; writing – review and editing: all authors.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. The animal study protocol was approved by the Ethics Committee of Laboratory Animals of the Children’s Hospital of Chongqing Medical University (protocol code CHCMU-IACUC20220429002).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional information

Funding

This work was supported by the Chongqing Yuzhong District Science and Technology Bureau [Grant Nos. 20200151 and cx2019078].